

1 November 2011

Approval of proposal to amend the terms of listing for bimatoprost, brimonidine tartrate with timolol maleate and prednisolone acetate

PHARMAC is pleased to announce the approval of an agreement with Allergan Australia Pty Ltd for four ophthalmological products. This proposal was the subject of a consultation letter dated 14 September 2011 which is available on our website at: <http://www.pharmac.govt.nz/2011/09/14/2011-09>.

In summary, the effect of the decision is that:

- There will be a reduction in the price and subsidy for bimatoprost (Lumigan) eye drops from 1 January 2012 with subsidy and delisting protection until 30 June 2015. A confidential rebate will apply.
- Brimonidine tartrate with timolol maleate (Combigan) eye drops will have subsidy and delisting protection until 30 June 2015. A confidential rebate will apply.
- Prednisolone acetate (Pred Mild and Pred Forte) will have subsidy and delisting protection until 30 June 2015.

Details of the proposal

Bimatoprost (Lumigan)

- The price and subsidy for Lumigan in Section B of the Pharmaceutical Schedule will be reduced from 1 January 2012 as follows (ex-manufacturer, exclusive of GST):

| Chemical | Presentation | Brand | Pack size | Current price and subsidy | Proposed price and subsidy from 1 Jan 2012 |
|-------------|----------------|---------|-----------|---------------------------|--|
| Bimatoprost | Eye drop 0.03% | Lumigan | 3 ml OP | \$19.50 | \$18.50 |

- A confidential rebate will apply to Lumigan.
- Lumigan will have subsidy and delisting protection until 30 June 2015.

Brimonidine tartrate with timolol maleate (Combigan)

- Combigan will remain fully funded in Section B of the Pharmaceutical Schedule at the current price and subsidy (ex-manufacturer, exclusive of GST):

| Chemical | Presentation | Brand | Pack size | Price and subsidy |
|---|--|----------|-----------|-------------------|
| Brimonidine tartrate with timolol maleate | Eye drops 0.2% with timolol maleate 0.5% | Combigan | 5 ml OP | \$18.50 |

- A confidential rebate will apply to Combigan.
- Combigan will have subsidy and delisting protection until 30 June 2015.

Prednisolone acetate (Pred Mild and Pred Forte)

- Pred Mild and Pred Forte will remain fully funded in Section B of the Pharmaceutical Schedule at the current prices and subsidies (ex-manufacturer, exclusive of GST):

| Chemical | Presentation | Brand | Pack size | Price and subsidy |
|----------------------|-----------------|------------|-----------|-------------------|
| Prednisolone acetate | Eye drops 0.12% | Pred Mild | 5 ml OP | \$4.50 |
| Prednisolone acetate | Eye drops 1% | Pred Forte | 5 ml OP | \$4.50 |

- Pred Mild and Pred Forte will have subsidy and delisting protection until 30 June 2015.

Feedback received

We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 29 September 2011 were considered in their entirety in making a decision on the proposed changes. All responses were supportive of the proposal.

More information

If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.